News & Events

Symbiosis starts producing sevuparin for Modus Therapeutics’ future clinical development in sepsis/septic shock

We’re very proud to announce that Symbiosis is working with Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, to manufacture their sevuparin drug product, securing the supply for the Phase II clinical development in sepsis/septic shock and other conditions driven by systemic inflammation.

Click here to find out more about this partnership: https://www.modustx.com/press-release?releaseIdentifier=F1DBF85B7C62D6DC

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.